Adipose-derived stromal vascular fraction injection for radiation-induced bladder fibrosis: a first-in-human pilot study
Stem Cells Translational Medicine · 2026
DOI: 10.1093/stcltm/szag002 ↗Kurz gefasst
Fallbericht in der Zeitschrift Stem Cells Translational Medicine, 2026. Verfasst von Roger Klein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States. Hauptthemen laut MEDLINE: Urinary Bladder, Adipose Tissue, Radiation Injuries, Urinary Bladder Diseases. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GID Bio Company at the UPMC Health System.
Abstract (Originalsprache)
Pelvic radiotherapy can lead to loss of bladder compliance, detrusor overactivity, and superficial vascular proliferation. Animal studies have demonstrated a reduction in radiation-induced inflammation and fibrosis following administration of mesenchymal stem cell products. We performed a first-in-human pilot study to assess the safety and feasibility of intravesical adipose stromal vascular fraction injection in an 82-year-old man with a history of brachytherapy for prostate cancer. Following FDA and IRB approval, subcutaneous adipose tissue harvested under local anesthesia was immediately processed using the SVF-2 device (GID Bio). The cell product, consisting of 4.58 × 107 stromal vascular fraction cells resuspended in 20 cc/s of lactated ringers, was injected into the bladder wall using a flexible cystoscope. Urinary symptoms, urologic flow parameters, repeat cystoscopy with bladder biopsy, and MRI were employed during the 16-month follow-up period. There were no postprocedural complications. The patient reported expected symptoms of self-limited dysuria, hematuria, and flank bruising in the 2 weeks following the procedure. Urinary symptoms and flow parameters remained stable for 6 months but progressed slightly at 15 months. A repeat cystoscopy with biopsy showed stabilization of disease without concern for secondary malignancy. The patient’s 12-month postprocedural MRI and 15-month urodynamics study were unchanged from prior. This study demonstrates the safety and feasibility of adipose harvest under local anesthesia, followed by point-of-care isolation and administration of an adipose-derived cell product via cystoscopic-guided intravesical injection. This pilot is foundational for further clinical studies to elucidate effective dosing and patient selection in the treatment of bladder fibrosis with cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States.
- Department of Plastic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States.
- The McGowan Institute of Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15213, United States.
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15213, United States.
ORCID-Profile: Roger Klein
Förderung
- GID Bio Company at the UPMC Health System
Zitieren
APA
Klein, R., Douglas, N., Ejaz, A., Rubin, J. P., & Rusilko, P. (2026). Adipose-derived stromal vascular fraction injection for radiation-induced bladder fibrosis: a first-in-human pilot study. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szag002
Vancouver
Klein R, Douglas N, Ejaz A, Rubin JP, Rusilko P. Adipose-derived stromal vascular fraction injection for radiation-induced bladder fibrosis: a first-in-human pilot study. Stem Cells Translational Medicine. 2026. doi:10.1093/stcltm/szag002
BibTeX
@article{Klein2026,
author = {Klein, Roger and Douglas, Nerone and Ejaz, Asim and Rubin, J Peter and Rusilko, Paul},
title = {Adipose-derived stromal vascular fraction injection for radiation-induced bladder fibrosis: a first-in-human pilot study},
journal = {Stem Cells Translational Medicine},
year = {2026},
doi = {10.1093/stcltm/szag002}
}
EUVIMED